Study of 68Ga-PSMA-CYC PET Imaging for Diagnosing and Staging Prostate Cancer Compared to Other PSMA Tracers

What this Trial Is About

Researchers are evaluating a new radiotracer called 68Ga-PSMA-CYC for imaging prostate cancer. This study aims to assess the safety, how the radiotracer spreads in the body, and its radiation dose. It also compares 68Ga-PSMA-CYC directly with two other radiotracers, 68Ga-PSMA-617 and 68Ga-PSMA-11, to see how well it performs in diagnosing prostate cancer. This study is conducted in patients who have confirmed prostate cancer, whether treated or untreated. Participants will receive PETCT scans using 68Ga-PSMA-CYC as well as either 68Ga-PSMA-617 or 68Ga-PSMA-11 within one week. The radiotracer dose is 3 to 4 mCi given intravenously. Dynamic PET scans start shortly after injection and continue at multiple time points up to 150 minutes to observe how the tracer distributes and targets prostate cancer lesions. During the study, patients will undergo imaging assessments to measure diagnostic value and monitor any adverse events within seven days after the PETCT scans. Radiation dosimetry data will be collected over approximately three months. The study includes safety monitoring and will measure how well the new tracer works compared to established ones. Participation lasts about one year on average for evaluation of diagnostic outcomes.

Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer